Do analysts prefer BBLG or AMIX?

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 897.62%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Autonomix Medical is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autonomix Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, BBLG or AMIX?

Bone Biologics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$1.37 N/A Autonomix Medical N/A N/A -$16.72M -$41.57 N/A

Is BBLG or AMIX more profitable?

Bone Biologics' return on equity of -57.87% beat Autonomix Medical's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% Autonomix Medical N/A -267.73% -216.75%

Do analysts rate BBLG or ZYXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zynex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BBLG or ZYXI more profitable?

Bone Biologics has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Bone Biologics' return on equity of -57.87% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% Zynex -68.35% -804.30% -36.67%

Do analysts recommend BJDX or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BJDX or BBLG?

Bone Biologics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$7.11 N/A Bone Biologics N/A N/A -$3.11M -$1.37 N/A

Is BJDX or BBLG more profitable?

Bone Biologics' return on equity of -57.87% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -125.00% -99.79% Bone Biologics N/A -57.87% -53.65%

Do analysts prefer BBLG or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BBLG or VSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TCTM Kids IT Education 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BBLG or VSA more profitable?

TCTM Kids IT Education's return on equity of 0.00% beat Bone Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% TCTM Kids IT Education N/A N/A N/A

Bone Biologics (BBLG) Competitors

$0.52 +0.02 (+3.22%)

Closing price 09/18/2026 03:57 PM Eastern

Extended Trading

$0.51 0.00 (-0.39%)

As of 09/18/2026 07:49 PM Eastern

Compare

BBLG vs. AMIX, ZYXI, BJDX, NXL, and VSA

Should you buy Bone Biologics stock or one of its competitors? Bone Biologics's main competitors and comparable companies include Autonomix Medical (AMIX), Zynex (ZYXI), Bluejay Diagnostics (BJDX), Nexalin Technology (NXL), and TCTM Kids IT Education (VSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bone Biologics compare to Autonomix Medical?

Bone Biologics (NASDAQ:BBLG) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

In the previous week, Autonomix Medical had 2 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Autonomix Medical and 0 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 0.00 beat Autonomix Medical's score of -0.12 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Neutral
Autonomix Medical	Neutral

Bone Biologics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Autonomix Medical	N/A	N/A	-$16.72M	-$41.57	N/A

Bone Biologics' return on equity of -57.87% beat Autonomix Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Autonomix Medical	N/A	-267.73%	-216.75%

Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1, indicating that its share price is 200% less volatile than the broader market.

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 5.0% of Bone Biologics shares are held by company insiders. Comparatively, 6.2% of Autonomix Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 897.62%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Autonomix Medical is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Bone Biologics beats Autonomix Medical on 7 of the 13 factors compared between the two stocks.

How does Bone Biologics compare to Zynex?

Bone Biologics (NASDAQ:BBLG) and Zynex (NASDAQ:ZYXI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Bone Biologics has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Bone Biologics' return on equity of -57.87% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Zynex	-68.35%	-804.30%	-36.67%

Zynex has higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

Bone Biologics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zynex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bone Biologics' average media sentiment score of 0.00 equaled Zynex'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
Zynex	Neutral

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 5.0% of Bone Biologics shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Zynex beats Bone Biologics on 6 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Bluejay Diagnostics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

In the previous week, Bluejay Diagnostics had 1 more articles in the media than Bone Biologics. MarketBeat recorded 1 mentions for Bluejay Diagnostics and 0 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 0.00 beat Bluejay Diagnostics' score of -0.35 indicating that Bone Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Bone Biologics	Neutral

Bone Biologics' return on equity of -57.87% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
Bone Biologics	N/A	-57.87%	-53.65%

Bone Biologics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 5.0% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Bone Biologics beats Bluejay Diagnostics on 6 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to Nexalin Technology?

Bone Biologics (NASDAQ:BBLG) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, Bone Biologics' average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
Nexalin Technology	Neutral

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 5.0% of Bone Biologics shares are held by insiders. Comparatively, 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bone Biologics has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Bone Biologics' return on equity of -57.87% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.95, indicating that its share price is 295% more volatile than the broader market.

Bone Biologics has higher earnings, but lower revenue than Nexalin Technology. Bone Biologics is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Nexalin Technology	$300K	11.92	-$8.22M	-$14.41	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bone Biologics beats Nexalin Technology on 6 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to TCTM Kids IT Education?

Bone Biologics (NASDAQ:BBLG) and TCTM Kids IT Education (NASDAQ:VSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

TCTM Kids IT Education's return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
TCTM Kids IT Education	N/A	N/A	N/A

Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, TCTM Kids IT Education has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, Bone Biologics' average media sentiment score of 0.00 equaled TCTM Kids IT Education'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
TCTM Kids IT Education	Neutral

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 49.8% of TCTM Kids IT Education shares are held by institutional investors. 5.0% of Bone Biologics shares are held by company insiders. Comparatively, 32.9% of TCTM Kids IT Education shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TCTM Kids IT Education has higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than TCTM Kids IT Education, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
TCTM Kids IT Education	$150K	18.63	$245.80M	$45.00	0.05

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TCTM Kids IT Education	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TCTM Kids IT Education beats Bone Biologics on 8 of the 9 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.43M	$5.57B	$7.24B	$13.21B
Dividend Yield	N/A	1.80%	2.57%	12.80%
P/E Ratio	-0.38	25.34	275.49	25.40
Price / Sales	N/A	43.73	639.55	86.82
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	0.17	5.69	10.46	6.33
Net Income	-$3.11M	$151.55M	$3.49B	$358.33M
7 Day Performance	-6.32%	0.66%	0.59%	1.12%
1 Month Performance	-14.71%	-3.33%	-1.74%	-2.39%
1 Year Performance	-75.55%	6.79%	18.13%	5.35%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	1.0423 of 5 stars	$0.52 +3.2%	N/A	-75.5%	$1.43M	N/A	N/A	2
AMIX Autonomix Medical	2.4751 of 5 stars	$4.28 +3.9%	$42.00 +881.3%	-81.1%	$4.00M	N/A	N/A	1	Short Interest Decrease
ZYXI Zynex	N/A	$0.13 flat	N/A	N/A	$3.80M	$108.20M	N/A	770
BJDX Bluejay Diagnostics	0.8576 of 5 stars	$0.85 +4.0%	N/A	-84.2%	$3.63M	N/A	N/A	9
NXL Nexalin Technology	0.85 of 5 stars	$5.10 +3.7%	N/A	-82.5%	$3.61M	$300K	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. AMIX, ZYXI, BJDX, NXL, and VSA

How does Bone Biologics compare to Autonomix Medical?

Summary

How does Bone Biologics compare to Zynex?

Summary

How does Bone Biologics compare to Bluejay Diagnostics?

Summary

How does Bone Biologics compare to Nexalin Technology?

Summary

How does Bone Biologics compare to TCTM Kids IT Education?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. AMIX, ZYXI, BJDX, NXL, and VSA

How does Bone Biologics compare to Autonomix Medical?

Does the media refer more to BBLG or AMIX?

Which has stronger valuation & earnings, BBLG or AMIX?

Is BBLG or AMIX more profitable?

Which has more volatility and risk, BBLG or AMIX?

Do institutionals & insiders hold more shares of BBLG or AMIX?

Do analysts prefer BBLG or AMIX?

Summary

How does Bone Biologics compare to Zynex?

Is BBLG or ZYXI more profitable?

Which has better earnings and valuation, BBLG or ZYXI?

Which has more volatility & risk, BBLG or ZYXI?

Do analysts rate BBLG or ZYXI?

Does the media favor BBLG or ZYXI?

Do institutionals and insiders believe in BBLG or ZYXI?

Summary

How does Bone Biologics compare to Bluejay Diagnostics?

Which has more volatility and risk, BJDX or BBLG?

Does the media refer more to BJDX or BBLG?

Is BJDX or BBLG more profitable?

Which has higher valuation & earnings, BJDX or BBLG?

Do analysts recommend BJDX or BBLG?

Do institutionals and insiders believe in BJDX or BBLG?

Summary

How does Bone Biologics compare to Nexalin Technology?

Does the media favor BBLG or NXL?

Do institutionals & insiders have more ownership in BBLG or NXL?

Is BBLG or NXL more profitable?

Which has more volatility & risk, BBLG or NXL?

Which has higher valuation & earnings, BBLG or NXL?

Do analysts prefer BBLG or NXL?

Summary

How does Bone Biologics compare to TCTM Kids IT Education?

Is BBLG or VSA more profitable?

Which has more volatility and risk, BBLG or VSA?

Does the media prefer BBLG or VSA?

Do insiders & institutionals believe in BBLG or VSA?

Which has better earnings & valuation, BBLG or VSA?

Do analysts prefer BBLG or VSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools